Company intelligence / Profile preview
Apogee Therapeutics
Waltham, MA, USapogeetherapeutics.gcs-web.com ↗
- Ownership
- Public · APGE
- Development stage
- Phase 2
01
Overview
Clinical-stage biotech advancing extended half-life biologics for inflammatory diseases. Lead candidate APG777 (anti-IL-13) shows77-day half-life in Phase1 and is in Phase2 trials for AD, with asthma and EoE trials planned. Pipeline includes combination therapies targeting multiple pathways.
- Therapeutic areas
- GastroenterologyPulmonologyDermatology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $8.4B
- Total revenue
- $0
- Enterprise value
- $7.4B
Beyond the preview
Go deeper on Apogee Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apogee Therapeutics.